Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Fiche publication
Date publication
octobre 2013
Journal
Breast (Edinburgh, Scotland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A
Lien Pubmed
Résumé
This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC) chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC).
Mots clés
Adult, Aged, Aged, 80 and over, Anthracyclines, therapeutic use, Antineoplastic Agents, adverse effects, Capecitabine, Chemotherapy, Adjuvant, Deoxycytidine, analogs & derivatives, Disease-Free Survival, Fatigue, chemically induced, Female, Fluorouracil, analogs & derivatives, Hand-Foot Syndrome, etiology, Humans, Indoles, adverse effects, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, drug therapy, Neutropenia, chemically induced, Paclitaxel, therapeutic use, Pyrroles, adverse effects, Survival Rate, Taxoids, therapeutic use, Thrombocytopenia, chemically induced, Triple Negative Breast Neoplasms, drug therapy
Référence
Breast. 2013 Oct;22(5):650-6